Uncovering Potential: Pacific Biosciences's Earnings Preview
Benzinga Insights 8 months ago
Earnings
Pacific Biosciences (NASDAQ:PACB) is preparing to release its quarterly earnings on Thursday, 2026-02-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Pacific Biosciences to report an earnings per share (EPS) of $-0.16.
The market awaits Pacific Biosciences's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Past Earnings Performance
The company's EPS beat by $0.03 in the last quarter, leading to a 7.05% drop in the share price on the following day.
Here's a look at Pacific Biosciences's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.15 | -0.17 | -0.19 | -0.21 |
| EPS Actual | -0.12 | -0.13 | -0.15 | -0.20 |
| Price Change % | -7.00 | 7.00 | -7.00 | 25.00 |
Tracking Pacific Biosciences's Stock Performance
Shares of Pacific Biosciences were trading at $1.81 as of February 10. Over the last 52-week period, shares are up 17.57%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Analyst Views on Pacific Biosciences
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Pacific Biosciences.
Analysts have given Pacific Biosciences a total of ratings, with the consensus rating being . The average one-year price target is $, indicating a potential .
To track all earnings releases for Pacific Biosciences visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.